Chemomab Therapeutics Ltd. (CMMB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CMMB currently has 575M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 85.28% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 23, 2026 |
20-F filing | 575.4M shares outstanding |
580M | 0 |
| Apr 04, 2025 |
20-F filing | 359.0M shares outstanding |
360M | 0 |
| Dec 02, 2024 |
POS AM filing: This prospectus relates to the proposed resale from time to time of up to 7,213,221 American Depositary Shares, or the ADSs, each representing 20 ordinary shares of no par value, or the Ordinary Shares, by the selling shareholders. |
290M | 0 |
| Aug 23, 2024 |
F-3 filing: This F-3 filing relates to the resale of 8,097,167 American Depositary Shares by the selling shareholders of Chemomab Therapeutics Ltd. |
290M | 0 |
| Mar 28, 2024 |
20-F filing | 284.1M shares outstanding |
280M | 0 |
| Oct 16, 2023 |
F-3 filing: Chemomab Therapeutics Ltd. is offering ordinary shares (including shares represented by American Depositary Shares), debt, warrants, or units, with an aggregate initial offering price not to exceed $200 million. |
230M | 0 |
| Jun 02, 2023 |
RW filing: Chemomab Therapeutics Ltd. requests the withdrawal of their Registration Statement on Form S-1, File Number 333-269218, as they have decided not to pursue the public offering at this time. |
11M | 35M |
| May 19, 2023 |
S-1/A filing: This S-1/A filing registers the offering of ADSs and pre-funded warrants, with Aegis Capital Corp. acting as the sole book-running manager. The company intends to use the net proceeds from this offering for continued clinical development of our product candidates, research activities, and for other general corporate purposes. |
11M | 39M |
| May 11, 2023 |
10-Q filing | 11.0M shares outstanding |
11M | 43M |
| Mar 22, 2023 |
S-1/A filing: This S-1/A filing registers the offering of American Depositary Shares (ADSs) and warrants by Chemomab Therapeutics Ltd. with Aegis Capital Corp. as the sole book-running manager, with the net proceeds to be used for clinical development, research, and general corporate purposes. |
11M | 43M |
| Mar 20, 2023 |
10-K filing | 227.6M shares outstanding |
230M | 0 |
| Feb 22, 2023 |
S-1/A filing: Chemomab Therapeutics Ltd. is offering up to 7,614,212 American Depositary Shares and warrants to purchase 7,614,212 American Depositary Shares in a combined offering. |
11M | 43M |
| Feb 21, 2023 |
S-1/A filing: Chemomab Therapeutics Ltd. is offering up to 7,614,212 American Depositary Shares and warrants to purchase 7,614,212 American Depositary Shares in a combined offering. |
11M | 43M |
| Nov 16, 2022 |
8-K filing: Chemomab Therapeutics Ltd. will repurchase 582,023 American Depositary Shares from its co-founders for approximately $1,213,400, following court approval, to cover their tax liabilities and mitigate market volatility. ($1.21M proceeds) |
12M | 35M |
| Nov 10, 2022 |
10-Q filing | 11.5M shares outstanding |
12M | 35M |
| Aug 12, 2022 |
10-Q filing | 11.4M shares outstanding |
11M | 35M |
| May 12, 2022 |
10-Q filing | 11.4M shares outstanding |
11M | 35M |
| Mar 30, 2022 |
10-K filing | 228.1M shares outstanding |
230M | 0 |
| Nov 12, 2021 |
10-Q filing | 11.4M shares outstanding |
11M | 35M |
| Aug 13, 2021 |
10-Q filing | 11.4M shares outstanding |
11M | 35M |
| May 13, 2021 |
10-Q filing | 37.1M shares outstanding |
37M | 9.4M |
| Apr 30, 2021 |
S-3 filing: Chemomab Therapeutics Ltd. may offer, issue and sell from time to time, in one or more offerings, ordinary shares, ADSs, debt, warrants or units, which they collectively refer to as the "securities." The aggregate initial offering price of the securities that they may offer and sell under this prospectus will not exceed $200 million. |
11M | 36M |
| Apr 15, 2021 |
S-3 filing: This prospectus relates to the proposed resale from time to time of up to 7,213,221 ADSs, each representing 20 Ordinary Shares, and warrants to purchase 261,929 American Depositary Shares Representing 5,238,580 Ordinary Shares, by the selling shareholders named herein. |
37M | 7.2M |
| Mar 09, 2021 |
10-K filing | 37.1M shares outstanding |
37M | 0 |
| Nov 16, 2020 |
10-Q filing | 37.1M shares outstanding |
37M | 0 |
| Aug 14, 2020 |
10-Q filing | 37.1M shares outstanding |
37M | 0 |
| May 07, 2020 |
10-Q filing | 37.1M shares outstanding |
37M | 0 |
| Mar 17, 2020 |
10-K filing | 37.1M shares outstanding |
37M | 0 |